These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16179087)

  • 1. Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.
    Zimmermann-Nielsen E; Grønbaek H; Dahlerup JF; Baatrup G; Thorlacius-Ussing O
    BMC Gastroenterol; 2005 Sep; 5():31. PubMed ID: 16179087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
    Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation in plasma before and after infliximab treatment in Crohn disease.
    Zimmermann-Nielsen E; Agnholt J; Thorlacius-Ussing O; Dahlerup JF; Baatrup G
    Scand J Gastroenterol; 2003 Oct; 38(10):1050-4. PubMed ID: 14621279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
    Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
    Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of genetic variants of mannan-binding (MBL) lectin-2 gene, MBL levels and function in ulcerative colitis and Crohn's disease.
    Sivaram G; Tiwari SK; Bardia A; Manoj G; Santhosh B; Saikant R; Aejaz H; Vishnupriya S; Khan AA; Habibullah C
    Innate Immun; 2011 Dec; 17(6):526-31. PubMed ID: 21088049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
    Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
    Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
    Ardizzone S; Bollani S; Bettica P; Bevilacqua M; Molteni P; Bianchi Porro G
    J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment.
    Teml A; Kratzer V; Schneider B; Lochs H; Norman GL; Gangl A; Vogelsang H; Reinisch W
    Am J Gastroenterol; 2003 Oct; 98(10):2226-31. PubMed ID: 14572572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease.
    Rector A; Lemey P; Laffut W; Keyaerts E; Struyf F; Wollants E; Vermeire S; Rutgeerts P; Van Ranst M
    Genes Immun; 2001 Oct; 2(6):323-8. PubMed ID: 11607788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
    Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
    Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel disease.
    Bak-Romaniszyn L; Szala A; Sokolowska A; Mierzwa G; Czerwionka-Szaflarska M; Swierzko AS; Zeman K; Cedzynski M
    Scand J Gastroenterol; 2011 Oct; 46(10):1275-8. PubMed ID: 21702710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum trefoil factors in patients with inflammatory bowel disease.
    Grønbaek H; Vestergaard EM; Hey H; Nielsen JN; Nexø E
    Digestion; 2006; 74(1):33-9. PubMed ID: 17068395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High plasma osteopontin levels in patients with inflammatory bowel disease.
    Mishima R; Takeshima F; Sawai T; Ohba K; Ohnita K; Isomoto H; Omagari K; Mizuta Y; Ozono Y; Kohno S
    J Clin Gastroenterol; 2007 Feb; 41(2):167-72. PubMed ID: 17245215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation mediated by mannan-binding lectin in plasma from healthy individuals and from patients with SLE, Crohn's disease and colorectal cancer. Suppressed activation by SLE plasma.
    Zimmermann-Nielsen E; Baatrup G; Thorlacius-Ussing O; Agnholt J; Svehag SE
    Scand J Immunol; 2002 Jan; 55(1):105-10. PubMed ID: 11841698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.